Wednesday, 11 December 2013

Melanoma & Skin Cancer News Round Up: 11/12/2013


A collection of links to articles referring to melanoma and skin cancer:

Skin cancer drug Vemurafenib approved for use
Stage III/IV melanoma patients at risk for new primaries
  • Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed in studies of dabrafenib and vemurafenib, according to research published online Dec. 2 in the Journal of Clinical Oncology.

Positive interim results reported for DNA-based therapy for advanced melanoma
  • Ziopharm Oncology announced encouraging interim results from a phase 1/2 multicenter trial of a novel DNA-based therapeutic candidate being studied with veledimex in patients with advanced melanoma.

Hopeful trials see firm's cancer vaccine bid reach the next level
  • CANCER vaccines developed by a Nottingham science firm are helping patients fight their tumours and survive longer, tests suggest.

Minorities and melanoma
  • Southern California has the third highest rate of melanoma in the world, only behind Australia and New Zealand. These statistics fly in the face of long-held conventional wisdom that skin cancer preys only on people with fair complexions. More than half of Southlanders are Latino, and nearly 10 percent are African-American.

U.S. midfielder Sacha Kljestan treated for pre-cancerous spots on face 
  • US men's national team footballer treated for Skin Cancer.




No comments:

Post a Comment